Increase in incidence of Duchenne muscular dystrophy (DMD) worldwide is the factor basically responsible for the growth of Duchenne muscular dystrophy market.
The researchers are pursuing strategies such as exon skipping, gene therapy, gene repair, and stop codon read-through. Continuous R&D activities regarding DMD treatment is helping in boosting the market revenue.
The companies operating in Duchenne muscular dystrophy (DMD) market are working toward development of mRNA therapy for Duchenne muscular dystrophy. They are also collaborating with research institutes to devise new therapies for DMD. Extensive investment is expected in this regard during the forecast period.
Duchenne muscular dystrophy (DMD) is referred to as a genetic disorder that is characterized by progressive muscle degeneration and weakness owing to alterations of protein called dystrophin that aids in keeping muscles intact. DMD is one amongst four conditions called dystrophinopathies.
The other three diseases belonging to the group are Becker Muscular Dystrophy (BMD, DMD’s mild form), an intermediate clinical presentation between DMD and BMD, and DMD-linked dilated cardiomyopathy (heart disease) with no or little skeletal, or voluntary muscle disease.
As per the National Organization for Rare Disorders (NORD), Duchenne muscular dystrophy is one of the rare muscle disorders but a frequent genetic condition, which is affecting one in 3,500 male births across the globe. It further states that nearly 2,000 children get diagnosed with DMD worldwide every year.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the Muscular Dystrophy Association, Duchenne muscular dystrophy (DMD) affects 6 per 100,000 people in North America and Europe. Research states that boys suffering from DMD could not survive beyond the teenage in the last few years.
Various awareness campaigns are being conducted to combat DMD. The key players are emphasizing launching of exon skipping technology, which is one of the significant factors catalyzing the Duchenne muscular dystrophy market.
There are various ongoing trials using diverse outcome measures for quantifying disease progression, which include 6-minute walking test, upper limb’s performance, time taken for rising from floor, time taken for climbing four steps, and north star ambulatory assessment code.
The Duchenne muscular dystrophy market is witnessing constructive disruption in the form of increasing R&D activities.
For instance, in June 2023, Sarepta Therapeutics Inc.’s ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus-based gene therapy, obtained an accelerated approval from the U.S. FDA. The therapy is targeting treatment of the ambulatory pediatric patients.
In May 2023, PepGen Inc. received a No Objection Letter (NOL) regarding its Clinical Trial Application (CTA) from Health Canada for Phase 2 CONNECT1-EDO51 study for initiating a multiple ascending dose (MAD) clinical trial of PGN-EDO51 in those suffering from DMD amenable to an exon 51 skipping approach.
In November 2023, six therapies witnessed approval in Europe to treat DMD, which include four exon-skipping drugs (casemersen, golodiresen, viltolarsen, and eteplirsen).
In January 2024, Sarepta Therapeutics, Inc. reported about positive data from the Part B of MOMENTUM study (Study SRP-5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that had enrolled patients aged between 8 and 21.
Continual R&D activities as mentioned above are thus driving the Duchenne muscular dystrophy industry demand.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest Duchenne muscular dystrophy market insights, North America dominated the Duchenne muscular degeneration landscape in 2023 and the dominance is expected to continue during the forecast period. This is attributed to growing number of clinical trials conducted in the U.S.
Asia Pacific’s Duchenne muscular dystrophy market share is ascribed to various initiatives being taken by the governments of Japan, South Korea, Australia, India, and China in this regard.
Rise in awareness regarding DMD and therapies/drugs available on this count is another factor driving the DMD genetic disorder market worldwide. The World Duchenne Awareness Day is observed on September 7 every year, in which several governmental and non-governmental organizations function as per the theme set by World Duchenne Organization.
The key players in Duchenne muscular dystrophy market are involved in new product launch followed by speedy approvals by the regulatory authorities to strengthen their position. For instance, in March 2024, Santhera Pharmaceuticals introduced AGAMREE (vamorolene) to treat Dechenne muscular dystrophy in the U.S.
In February 2024, BioMarin conducted a multi-center, open-label study comprising two parts for evaluating tolerability and safety of BMN 351 at the escalating doses in patients contracting DMD with genetic mutations amenable to exon 51 skipping.
Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi, and Sarepta Therapeutics, Inc. are covered in the Duchenne muscular dystrophy market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.2 Bn |
| Market Forecast (Value) in 2034 | US$ 7.4 Bn |
| Growth Rate (CAGR) | 11.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.2 Bn in 2023
It is projected to grow at a CAGR of 11.7% from 2024 to 2034
Growing prevalence of Duchenne muscular dystrophy and increase in R&D activities
Hospitals segment accounted for the largest share in 2023
North America was the dominant region in 2023
Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi, and Sarepta Therapeutics, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Duchenne Muscular Dystrophy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Molecular-based Therapies
6.3.2. Steroid Therapy
6.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
6.3.4. Physical Therapy
6.3.5. Others (Surgery, etc.)
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Others (Research Institutes, etc.)
7.4. Market Attractiveness Analysis, by End-user
8. Global Duchenne Muscular Dystrophy Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Duchenne Muscular Dystrophy Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2020-2034
9.3.1. Molecular-based Therapies
9.3.2. Steroid Therapy
9.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
9.3.4. Physical Therapy
9.3.5. Others (Surgery, etc.)
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Others (Research Institutes, etc.)
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment Type
9.6.2. By End-user
9.6.3. By Country
10. Europe Duchenne Muscular Dystrophy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Molecular-based Therapies
10.3.2. Steroid Therapy
10.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
10.3.4. Physical Therapy
10.3.5. Others (Surgery, etc.)
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Duchenne Muscular Dystrophy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Molecular-based Therapies
11.3.2. Steroid Therapy
11.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
11.3.4. Physical Therapy
11.3.5. Others (Surgery, etc.)
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Duchenne Muscular Dystrophy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Molecular-based Therapies
12.3.2. Steroid Therapy
12.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.3.4. Physical Therapy
12.3.5. Others (Surgery, etc.)
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Duchenne Muscular Dystrophy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Molecular-based Therapies
13.3.2. Steroid Therapy
13.3.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.3.4. Physical Therapy
13.3.5. Others (Surgery, etc.)
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Mylan N.V.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Fresenius Kabi AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Hikma Pharmaceuticals plc
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Novartis AG
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Teva Pharmaceutical Industries Ltd.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Bristol Myers Squibb Company
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GSK plc
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Bayer AG
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
14.3.11. Sun Pharmaceutical Industries Ltd.
14.3.11.1. Company Overview
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Financial Overview
14.3.11.5. Strategic Overview
14.3.12. Boehringer Ingelheim
14.3.12.1. Company Overview
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Financial Overview
14.3.12.5. Strategic Overview
14.3.13. Sanofi
14.3.13.1. Company Overview
14.3.13.2. Product Portfolio
14.3.13.3. SWOT Analysis
14.3.13.4. Financial Overview
14.3.13.5. Strategic Overview
14.3.14. Sarepta Therapeutics, Inc.
14.3.14.1. Company Overview
14.3.14.2. Product Portfolio
14.3.14.3. SWOT Analysis
14.3.14.4. Financial Overview
14.3.14.5. Strategic Overview
List of Tables
Table 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 02: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 03: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 04: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 05: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 06: North America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 07: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 08: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 09: Europe Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 10: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 11: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 12: Asia Pacific Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 15: Latin America Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 18: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Duchenne Muscular Dystrophy Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 03: Global Duchenne Muscular Dystrophy Market Value Share, by Treatment Type, 2023
Figure 04: Global Duchenne Muscular Dystrophy Market Revenue (US$ Bn), by End-user, 2023
Figure 05: Global Duchenne Muscular Dystrophy Market Value Share, by End-user, 2023
Figure 06: Global Duchenne Muscular Dystrophy Market Value Share, by Region, 2023
Figure 07: Global Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast, 2020-2034
Figure 08: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 09: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 10: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 11: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 12: Global Duchenne Muscular Dystrophy Market Value Share Analysis, by Region, 2023 and 2034
Figure 13: Global Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Region, 2023-2034
Figure 14: North America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 15: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country, 2023-2034
Figure 16: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country, 2023 and 2034
Figure 17: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 18: North America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 19: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 20: North America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 21: Europe Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 22: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 23: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 24: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 25: Europe Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 26: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 27: Europe Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 28: Asia Pacific Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 29: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 30: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 31: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 32: Asia Pacific Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 34: Asia Pacific Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 35: Latin America Duchenne Muscular Dystrophy Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 36: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 37: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 38: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 39: Latin America Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 41: Latin America Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Figure 42: Middle East & Africa Duchenne Muscular Dystrophy Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 43: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 44: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 45: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 46: Middle East & Africa Duchenne Muscular Dystrophy Market Value Share Analysis, by End-user, 2023 and 2034
Figure 47: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 48: Middle East & Africa Duchenne Muscular Dystrophy Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Duchenne Muscular Dystrophy Market
